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Abstract Parkinson’s disease (PD) is a chronic progres-
sive neurological disorder characterized by resting tremor,
rigidity, bradykinesia, gait disturbance, and postural
instability. Levodopa, the precursor to dopamine, coad-
ministered with carbidopa or benserazide, aromatic amino
acid decarboxylase inhibitors, is the most effective and
widely used therapeutic agent in the treatment of PD. With
continued levodopa treatment, a majority of patients
develop motor complications such as dyskinesia and motor
‘on-off’ fluctuations, which are, in part, related to the
fluctuations in plasma concentrations of levodopa. A new
extended-release (ER) carbidopa–levodopa capsule product
(also referred to as IPX066) was developed and approved
in the US as Rytary and in the EU as Numient. The
capsule formulation is designed to provide an initial rapid
absorption of levodopa comparable to immediate-release
(IR) carbidopa–levodopa, and to subsequently provide
stable levodopa concentrations with reduced peak-to-
trough excursions in plasma concentrations in order to
reduce motor fluctuations associated with pulsatile stimu-
lation of dopamine receptors and to minimize dyskinesia.
Phase III studies of this ER carbidopa–levodopa capsule
formulation in patients with PD have shown a significant
reduction in ‘off’ time compared with IR carbidopa–levo-
dopa and carbidopa–levodopa–entacapone. We present a
review of the clinical pharmacokinetics and
pharmacodynamics of this ER product of carbidopa–levo-
dopa in healthy subjects and in patients with PD.
Key Points
Rytary (Numient, IPX066) is an extended-release
(ER) capsule formulation of carbidopa–levodopa
that combines immediate-release (IR) and ER beads
to provide a rapid onset of effect that is then
sustained for a longer duration than standard
formulations of carbidopa–levodopa.
For comparable doses of levodopa, Rytary results
in 30% maximum observed plasma concentration
and 70% area under the concentration–time curve
compared with IR levodopa.
Rytary and IR carbidopa–levodopa have a similar
concentration–effect relationship based on the
Unified Parkinson’s Disease Rating Scale Part III,
and finger tapping rate.
1 Introduction
Parkinson’s disease (PD) is characterized by the progres-
sive degeneration of nigrostriatal dopaminergic neurons.
Levodopa (L-3,4-dihydroxyphenylalanine), the metabolic
precursor of dopamine, in combination with aromatic
amino acid decarboxylase (AADC) inhibitors such as car-
bidopa or benserazide, is considered the most effective
treatment for management of the loss of mobility associ-
ated with PD.
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The oral absorption, central nervous system (CNS)
penetration, and distribution of levodopa are mediated by
active transporters. Levodopa is actively absorbed and
transported across the intestinal mucosa and blood–brain
barrier (BBB). L- and B(0,?)-type amino acid transporters
(LAT1, LAT2, rBAT, and their oligomers with the
heterologous proteins 4F2hc, TAT1, and OCT) have been
implicated in the oral and CNS absorption of levodopa
[1–4]. The absorption of levodopa is restricted to the upper
small intestine. Once absorbed, levodopa is converted to
dopamine by AADC and is metabolized to 3-O-methyldopa
(3-OMD) by catechol-O-methyltransferase (COMT),
among other metabolites. Inhibitors of AADC and COMT
are coadministered with levodopa to suppress the periph-
eral formation of dopamine, reduce the exogenous dose of
levodopa by maximizing the amount of levodopa trans-
ported across the BBB, and reduce adverse effects of
peripheral dopamine, such as nausea and hypotension.
Continuous stimulation of striatal dopaminergic recep-
tors remains the goal and is a current unmet need of oral
pharmacotherapy for PD. With progression of PD and
chronic therapy, levodopa is often associated with the
development of involuntary motor function complications
such as ‘on-off’ phenomena, ‘wearing-off’, and dyskinetic
movements. The most common form of dyskinesia, termed
‘peak-dose dyskinesia’, coincides with peak plasma levels
of levodopa. Although a number of factors contribute to the
development of motor complications in levodopa therapy,
pulsatile levodopa administration and high levodopa doses
are considered key factors [5–7].
Multiple therapeutic strategies, including oral con-
trolled-release (CR) formulations and intestinal/jejunal
infusion, have been attempted to provide continuous and
sustained oral delivery of levodopa in an effort to reduce or
delay the development of dyskinesias. Current oral CR
products such Sinemet CR, which is absorbed over 4–6 h,
are associated with erratic absorption and variable levo-
dopa plasma concentrations. The absorption of Sinemet
CR is less predictable than that of Sinemet immediate-
release (IR) and may require supplemental doses of IR
carbidopa–levodopa [8]. The effect of Sinemet CR on
dyskinesias is also often difficult to predict. Continuous
controlled oral delivery of levodopa has been a challenge
due to its short plasma half-life, unreliable absorption due
to delayed and/or variable gastric emptying, variable
in vivo dissolution of levodopa products, and absorption
being limited to the small intestine where the transporters
for levodopa are located. Gastrointestinal dysfunction is a
key non-motor symptom in PD across all stages of PD,
with studies reporting impaired gastric emptying and con-
stipation. Gastroparesis is observed in 70–100% of subjects
[9, 10] and can lead to response fluctuations, including
delayed ‘on’ or lack of an ‘on’ (no ‘on’ phenomenon), and
there is a clear relationship between gastric emptying and
levodopa absorption [11].
Although dopamine agonists have longer plasma half-
lives than levodopa, cause less pulsatile stimulation of
dopamine receptors, and are used for therapy in the earlier
stages of PD, they are not as efficacious as levodopa and
suffer from common side effects. The use of COMT inhi-
bitors, such as entacapone, with carbidopa–levodopa
reduces ‘off’ time but large fluctuations in levodopa plasma
concentrations still occur in their presence [12, 13]. Enta-
capone also adversely affects the rate at which dyskinesias
develop on carbidopa–levodopa treatment when started
early in disease [14]. Levodopa remains indispensable in
the treatment of PD, especially in the later stages of the
disease, and there is a clinical need for an improved oral
carbidopa–levodopa product that can consistently deliver
stable levodopa plasma concentrations.
The development program for this new extended-release
(ER) capsule formulation of carbidopa–levodopa (also
referred to as IPX066) included studies to characterize the
pharmacokinetics in healthy volunteers and patients with
PD, and to evaluate dose proportionality, and the effect of
food and intrinsic factors on the pharmacokinetics. Both
the safety and efficacy of this ER carbidopa–levodopa
product have been reported previously [15–17]. This
review focuses on the integrated pharmacokinetic and
pharmacodynamic properties of this ER capsule formula-
tion of carbidopa–levodopa.
2 Drug Formulation
IPX066, an ER capsule formulation of carbidopa–levodopa
(Rytary in the US and Numient in the EU), is designed
to provide a plasma profile characterized by an initial rapid
increase in levodopa concentrations followed by sustained
levodopa concentrations with minimal peak-to-trough
fluctuations. This profile provides a rapid onset of effect
and reduces ‘off’ time in PD subjects. The formulation is a
combination of levodopa and carbidopa at a ratio of 4:1 and
is available in four strengths: 23.75/95, 36.25/145, 48.75/
195, and 61.25/245 mg carbidopa–levodopa. The formu-
lation contains four components: an IR component, ER
component 1, ER component 2, and a functional excipient
component. The IR component, ER component 1, and ER
component 2 contain both levodopa and carbidopa as
active ingredients, while the fourth component does not
contain levodopa or carbidopa but includes tartaric acid as
a functional excipient serving as an acidifying agent
designed to facilitate the absorption of levodopa. The
four components of the ER carbidopa–levodopa formula-
tion exhibit different individual drug-release characteristics
and are designed to deliver the initial increase in levodopa
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concentrations and provide the sustained plasma profile.
Early in development, pharmacokinetic studies were con-
ducted in healthy volunteers to evaluate various combina-
tions of IR and formulations designed to release levodopa
over a range of durations to allow selection of the desired
in vivo levodopa profile. Figure 1 presents the plasma
concentration profile for IR levodopa, ER component 1
beads, and ER component 2 beads at levodopa doses from
the individual components that would correspond to a total
dose of 390 mg. Also presented is the pharmacokinetic
profile for a single dose of 390 mg ER carbidopa–levodopa
intact capsule (two capsules of levodopa 195 mg). The
combination of the IR and two ER formulation components
allows achievement of the desired levodopa pharmacoki-
netic profile characterized by a rapid initial increase fol-
lowing by sustained levodopa plasma concentrations.
3 Pharmacokinetics
The clinical development program to characterize the
pharmacokinetics and pharmacodynamics of ER car-
bidopa–levodopa included the following goals:
• characterize the single and multiple dose pharmacoki-
netics and pharmacodynamics relative to IR carbidopa–
levodopa in patients with PD;
• characterize the single dose pharmacokinetics and
pharmacodynamics relative to CR carbidopa–levodopa
and relative to carbidopa–levodopa–entacapone in
patients with PD;
• study the single-dose pharmacokinetics relative to other
marketed carbidopa–levodopa formulations in healthy
volunteers;
• evaluate the effect of food and of emptying the capsule
contents onto soft foods such as applesauce;
• study the dose proportionality of the pharmacokinetics;
• characterize the effects of intrinsic factors such as age,
gender, and weight on the pharmacokinetics
3.1 Single-Dose Pharmacokinetics in Healthy Adults
The single-dose pharmacokinetics of ER carbidopa–levo-
dopa capsules was compared with the pharmacokinetics of
other currently available formulations of carbidopa–levo-
dopa in healthy subjects in an open-label, randomized,
crossover study [18]. Subjects received a single oral dose
of ER carbidopa–levodopa (two capsules of 48.75/195 mg
carbidopa–levodopa), IR carbidopa–levodopa (25/100 mg
Sinemet), CR carbidopa–levodopa (25/100 mg Sinemet
CR) or carbidopa–levodopa–entacapone (25/100/200 mg
Stalevo) under fasting conditions. The levodopa dose of
ER carbidopa–levodopa (390 mg) was chosen to approxi-
mately match the expected peak levodopa concentrations
for IR carbidopa–levodopa [18]. With ER carbidopa–
levodopa capsules, levodopa plasma concentrations
increased rapidly, reaching an initial peak at approximately
1 h, with mean time to maximum concentration (tmax)
occurring at approximately 4.5 h, after which levodopa
concentrations decreased slowly and were\10% of peak at
approximately 10 h. The pharmacokinetics of levodopa
from the different formulations are summarized in Table 1.
In spite of a 3.9-fold higher levodopa dose with ER car-
bidopa–levodopa compared with the other treatments, peak
levodopa concentrations were approximately 1.2- to 1.6-
fold higher. As expected, area under the concentration–
time curve (AUC) values were approximately 2.2- to 3-fold
higher. The bioavailability of levodopa from ER car-
bidopa–levodopa capsules relative to IR carbidopa–levo-
dopa, CR carbidopa–levodopa, and carbidopa–levodopa–
entacapone was 83.5, 78.3, and 58.8%, respectively. In
comparison, on a dose-normalized basis, peak plasma
concentrations of levodopa from ER carbidopa–levodopa
relative to IR carbidopa–levodopa, CR carbidopa–levo-
dopa, and carbidopa–levodopa–entacapone were 31.3,
40.0, and 33.4%, respectively. The absolute bioavailability
of levodopa from IR carbidopa–levodopa has been reported
to be 84% [19]. Hence, the absolute bioavailability of
levodopa from ER carbidopa–levodopa capsules is
approximately 70% (the 83.5% bioavailability of levodopa
from ER carbidopa–levodopa relative to IR carbidopa–
levodopa multiplied by 0.84).
Fig. 1 Pharmacokinetic profile for immediate-release CD-LD, indi-
vidual extended-release components and intact capsules of Rytary.
Data presented are LD concentrations from different studies that
evaluated the performance of individual components and the phar-
macokinetics of extended-release CD-LD capsules. CD carbidopa, LD
levodopa
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3.2 Single-Dose Pharmacokinetics in Patients
with Parkinson’s Disease (PD)
The single-dose pharmacokinetics of ER carbidopa–levo-
dopa capsules in patients with PD was investigated relative
to IR carbidopa–levodopa (Sinemet), CR carbidopa–
levodopa (Sinemet CR), and carbidopa–levodopa–enta-
capone (Stalevo), each in a separate crossover study
[17, 20]. In these studies, patients took a single dose of
their typical pre-study IR carbidopa–levodopa regimen
following an overnight fast on one occasion, and ER car-
bidopa–levodopa on a separate occasion. The dose of ER
carbidopa–levodopa was based on a conversion designed to
achieve similar peak levodopa concentrations as the com-
parator treatments. Based on pharmacokinetic data in
healthy volunteers that ER carbidopa–levodopa results in
dose-adjusted levodopa maximum observed plasma con-
centrations (Cmax) that are approximately 31.3% on IR
carbidopa–levodopa, it was expected that the ER levodopa
doses would be at least twofold higher. Figure 2 presents
the levodopa plasma concentration–time profile following
single doses of IR carbidopa–levodopa and ER carbidopa–
levodopa capsules. As noted in healthy subjects, levodopa
concentrations peaked within approximately 1 h and then
decreased rapidly following IR carbidopa–levodopa. With
ER carbidopa–levodopa capsules, the initial increase in
levodopa concentrations was similar to that noted with IR
levodopa, but levodopa concentrations were sustained for
4–5 h following the peak. In addition, in spite of an
approximate two- to five-fold higher levodopa dose with
ER carbidopa–levodopa, peak levodopa concentrations
were comparable to IR dosing. The single-dose pharma-
cokinetics of ER carbidopa–levodopa and the other car-
bidopa–levodopa products in patients are presented in
Table 2. On a dose-normalized basis, the levodopa Cmax
from ER carbidopa–levodopa compared with IR car-
bidopa–levodopa, CR carbidopa–levodopa, and carbidopa–
levodopa–entacapone were 30.5, 52.2, and 29.7%, respec-
tively. The bioavailability of levodopa from ER carbidopa–
levodopa relative to IR carbidopa–levodopa and car-
bidopa–levodopa–entacapone was 69 ± 23 and 47 ± 16,
respectively. Due to the short sampling duration in the
pharmacokinetic study, the bioavailability of levodopa
from ER carbidopa–levodopa relative to CR carbidopa–
levodopa was not estimated.
3.3 Multiple-Dose Pharmacokinetics in Patients
with PD
Multiple-dose pharmacokinetics of ER carbidopa–levo-
dopa compared with IR carbidopa–levodopa was charac-
terized in patients with advanced PD [20]. Patients received
an individualized dosing regimen of ER carbidopa–levo-
dopa and IR carbidopa–levodopa for 8 days in a crossover
fashion, with multiple-dose pharmacokinetic assessment
carried out over 12 h on the last day of each treatment
Table 1 Single-dose pharmacokinetic parameters for levodopa in healthy subjects (n = 22) Adapted from Hsu et al. [18]
Producta Cmax (ng/mL) tmax (h)
b AUC? (ng h/mL) t (h) Cmax ratio F (%)
ER CD-LD 390 mg 1326 ± 268 4.5 (0.5–8.0) 7244 ± 2553 1.9 ± 0.7 – –
IR CD-LD 100 mg 1094 ± 401 1.0 (0.5–2.0) 2251 ± 664 1.6 ± 0.2 0.34 ± 0.10 83.5 ± 21
CR CD-LD 100 mg 855 ± 299 1.5 (1.0–2.0) 2403 ± 680 1.6 ± 0.2 0.43 ± 0.16 78.3 ± 20
CD-LD-Entacapone 100 mg 1027 ± 284 1.5 (1.0–2.0) 3291 ± 1149 1.6 ± 0.2 0.35 ± 0.11 58.8 ± 18
ER extended-release, IR immediate-release, CR sustained release, LD levodopa, CD carbidopa; Cmax maximum observed plasma concentration,
tmax time to maximum concentration, t half-life, Cmax ratio dose-normalized ratio of ER CD-LD Cmax to reference product, AUC? area under
the concentration–time curve extrapolated to infinity, F relative bioavailability
a The doses listed are for levodopa
b Median (range)
Fig. 2 Single-dose pharmacokinetics of IR and ER CD-LD in
patients with Parkinson’s disease. ER extended-release, IR immedi-
ate-release, CD carbidopa, LD levodopa
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period. During the first 3 days of each treatment period, the
dosing regimen (dose and frequency) was adjusted as
necessary to achieve optimal efficacy with reduced adverse
effects. For the ER carbidopa–levodopa capsule treatment,
89% of patients took one or two doses, and 11% took three
doses over the 12-h assessment period, with no subject
taking more than four doses. In contrast, during the IR
carbidopa–levodopa treatment, 37% of patients took one or
two doses, 26% took three doses, and 37% took four or
more doses over the 12-h assessment period. Figure 3
presents the multiple-dose levodopa concentration–time
profile for ER carbidopa–levodopa and IR carbidopa–
levodopa over the 12-h assessment period. Multiple dose
pharmacokinetics of ER and IR carbidopa–levodopa are
summarized in Table 3. The magnitude of rise and fall of
levodopa plasma concentrations relative to the average
concentration (i.e. the fluctuation index) may be of par-
ticular interest for an ER formulation. The lower the fluc-
tuation index, the more likely the Cmax is blunted relative to
the trough, thus improving the pharmacodynamic profile
and minimizing Cmax-related adverse effects [21]. The
fluctuation index measured as (Cmax - Cmin)/Cave was 1.5
and 3.2 for ER carbidopa–levodopa and IR carbidopa–
levodopa, respectively. Both treatments had a similar
accumulation ratio indicating that the ER formulation does
not result in accumulation of levodopa when administered
approximately every 6 h in accordance with the prescribing
guidelines.
3.4 Dose Proportionality
The dose proportionality of ER carbidopa–levodopa cap-
sules was evaluated in a single-dose, open-label,
Table 2 Single-dose
pharmacokinetics of ER CD-LD
in patients with PD compared
with other CD-LD products
Product Cmax (ng/mL) tmax (h)
a AUC? (ng h/mL) t (h)
ER CD-LD capsules
LD 435 mg (n = 12) 1686 ± 970 1.5 (1–6) – –
LD 490 mg (n = 16) 2424 ± 763 2.5 (0.5–4) 11291 ± 3945 1.6 ± 0.5
LD 585 mg (n = 7) 2936 ± 1360 1.5 (0.5–2.5) 15210 ± 8905 2.4 ± 0.9
LD 735 mg (n = 14) 3058 ± 701 1.5 (0.5–3) 13221 ± 3756 1.5 ± 0.2
LD 780 mg (n = 3) 3703 ± 1220 2 (0.5–2.5) 18424 ± 4093 2.2 ± 1
LD 980 mg (n = 6) 4967 ± 1040 2 (0.5–4.5) 20479 ± 3257 1.7 ± 0.1
IR CD-LD
LD 100 mg (n = 11) 1870 ± 697 0.5 (0.5–1.5) 3173 ± 1090 1.5 ± 0.4
LD 200 mg (n = 10) 2331 ± 769 1.3 (0.5–2) 5978 ± 1830 1.5 ± 0.2
LD 250 mg (n = 4) 3935 ± 1570 0.5 (0.5–1) 7690 ± 1090 1.6 ± 0.1
CR CD-LD
LD 200 mg (n = 12) 1453 ± 814 2 (1–4) 5000 ± 3070b –
CD-LD-Entacapone
LD 100 mg (n = 10) 2105 ± 897 1 (0.5–1.5) 7223 ± 3640 1.8 ± 0.3
LD 150 mg (n = 6) 2493 ± 837 1 (0.5–2) 8655 ± 5320 1.8 ± 0.2
LD 200 mg (n = 4) 3038 ± 756 1.3 (1–2) 10936 ± 3924 1.7 ± 0.4
The pharmacokinetics for ER CD-LD capsules are based on data integrated from three studies
Cmax maximum observed plasma concentration, tmax time to maximum concentration, t half-life, AUC?
area under the concentration–time curve extrapolated to infinity, CD carbidopa, LD levodopa, ER extended-
release, IR immediate-release, CR controlled-release, PD Parkinson’s disease
a Median (range)
b AUCt reported
Fig. 3 Multiple-dose pharmacokinetics of IR and ER CD-LD in
patients with Parkinson’s disease. Arrows represent oral dose
administrations every 3 or 6 h. ER extended-release, IR immediate-
release, CD carbidopa, LD levodopa, Qxh every x hours
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randomized, crossover study in healthy subjects [22]. ER
carbidopa–levodopa was provided as one capsule of each
dose strength (levodopa 95, 145, 195, 245 mg), and each
subject received a single dose of each treatment with
240 mL of room-temperature water under fasted conditions
in a randomized sequence. Dose proportionality was
assessed using a power model (Y = a 9 [Dose]b), as
described by Gough et al. [23], with the modification by
Smith et al. [24] Dose proportionality was to be concluded
if the proportionality exponent estimate (b) for levodopa
Cmax and AUC was close to unity and the 90% confidence
intervals (CIs) were within the acceptance interval
(0.7645–1.2355).
A total of 31 healthy subjects were enrolled; 28 subjects
received all four treatments and were included in the sta-
tistical analysis. Online Resource Table 1 presents the
pharmacokinetic and dose-proportionality analysis. ER
carbidopa–levodopa showed dose-proportional pharma-
cokinetics over the capsule strength range of 95/245 mg of
levodopa. The power-model analysis confirmed that the
90% CI for the proportionality exponent estimate (b) for
Cmax, AUCt, and AUC? were within the acceptance
interval, indicating dose proportional pharmacokinetics.
Dose proportionality of the ER carbidopa–levodopa
capsules was also examined using the pooled single-dose
pharmacokinetic data in patients with advanced PD from
the pharmacokinetic cohort enrolled in the efficacy studies.
Levodopa Cmax and AUC? increased in an approximate
dose-proportional fashion over the broad range of doses
administered (Fig. 4).
3.5 Comparison of Pharmacokinetics in Healthy
Subjects and Patients with PD
The pharmacokinetics of ER carbidopa–levodopa capsules
has been studied in multiple studies in healthy volunteers
[18, 22] and in patients with advanced PD [17, 20]. Table 4
summarizes the levodopa pharmacokinetics in healthy
subjects and in patients following normalization to a
levodopa dose of 245 mg. Modest differences were noted
in the levodopa pharmacokinetics of ER carbidopa–levo-
dopa between healthy subjects and patients with PD. Mean
dose-normalized levodopa AUC? and Cmax were higher
Table 3 Multiple-dose
pharmacokinetics of ER CD-LD
and IR CD-LD in patients with
PD
Product Cmax (ng/mL) Cave (ng/mL) Accumulation Fluctuation
ER CD-LD capsules
LD 490 mg (n = 7) 3227 ± 1089 1623 ± 518 1.3 ± 0.4 1.7 ± 0.4
LD 735 mg (n = 11) 4166 ± 1787 2316 ± 777 1.3 ± 0.8 1.4 ± 0.4
IR CD-LD
LD 100 mg (n = 11) 2209 ± 744 741 ± 203 1.1 ± 0.3 3.0 ± 1.1
LD 200 mg (n = 9) 3057 ± 1108 969 ± 384 1.1 ± 0.3 3.3 ± 1.0
Cmax maximum observed plasma concentration, Cave average concentration over 12 h, Accumulation drug
accumulation, Fluctuation fluctuation calculated as (Cmax - Cmin)/Cave, ER extended-release, IR imme-
diate-release, CD carbidopa, LD levodopa, PD Parkinson’s disease
Fig. 4 Relationship between LD dose and LD pharmacokinetics in
patients with Parkinson’s disease. Cmax maximum observed plasma
concentration, AUC? area under the concentration–time curve
extrapolated to infinity, LD levodopa
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(approximately 44 and 38% for AUC? and Cmax, respec-
tively) in subjects with PD compared with healthy subjects.
The elimination half-life for levodopa was comparable in
the two populations.
3.6 Maintenance of Levodopa Plasma
Concentrations
The ER carbidopa–levodopa capsule formulation is
designed to provide an initial increase in levodopa con-
centrations that are comparable to IR carbidopa–levodopa
and subsequently maintain the levodopa concentration for
an extended period of time. Table 5 summarizes the
duration of time levodopa plasma concentrations are sus-
tained above 50% of Cmax in both healthy subjects and
patients with PD for ER carbidopa–levodopa and other
marketed carbidopa–levodopa products following a single
dose.
ER carbidopa–levodopa sustains levodopa plasma con-
centrations above 50% of Cmax for a longer duration
(4–5 h) than IR carbidopa–levodopa (approximately 1.5 h),
CR carbidopa–levodopa (2–3 h), and carbidopa–levodopa–
entacapone (2–2.5 h) in healthy subjects and subjects with
PD. Notably, the estimated duration that concentrations are
sustained above 50% Cmax was consistent across the
studies and in both healthy volunteers and patients with
PD. Consistent with the sustained levodopa concentrations,
the duration of pharmacodynamic effect following ER
carbidopa–levodopa capsules is approximately 2 h longer
than that for IR carbidopa–levodopa or carbidopa–levo-
dopa–entacapone for both tapping and Unified Parkinson’s
Disease Rating Scale (UPDRS) Part III (motor function)
scores [17, 20].
3.7 Low Variability in Pharmacokinetics
Variability (percentage of coefficient of variation) in
levodopa pharmacokinetics may be estimated as a ratio of
the standard deviation (SD) and mean. Table 6 summarizes
the variability in levodopa pharmacokinetics for ER car-
bidopa–levodopa capsules compared with other levodopa
products from the study in healthy volunteers [18]. Inter-
subject variability in Cmax was lower, and for AUCt was
lower or comparable for ER carbidopa–levodopa capsules
than for other carbidopa–levodopa products.
Several studies conducted in healthy volunteers as part
of the development of ER carbidopa–levodopa capsules
involved a crossover design that allowed estimation of
intersubject (between subject) and intrasubject (within
subject) variability. Natural logarithmically-transformed
dose-normalized Cmax and AUC? were analyzed by anal-
ysis of variance using a linear mixed model to obtain
Table 4 Summary of dose-normalized levodopa pharmacokinetics in healthy subjects and patients with PD following ER CD-LD
Cmax (ng/mL) tmax (h)
a AUC? (ng h/mL) t (h)
Healthy subjects (N = 184) 822 ± 259 4.0 (0.3–8.0) 3884 ± 1285 1.7 ± 0.7
PD patients (N = 72) 1130 ± 484 2.0 (0.5–6.0) 5579 ± 2465 1.9 ± 0.7b
Cmax and AUC? are dose-normalized to 245 mg
Cmax maximum observed plasma concentration, tmax time to maximum concentration, AUC? area under the concentration–time curve extrap-
olated to infinity, t half-life, ER extended-release, CD carbidopa, LD levodopa, PD Parkinson’s disease
a Median (range)
b N = 59
Table 5 Comparison of duration of time (hours) the LD concentrations are sustained above 50% of Cmax by CD-LD products following a single
dose. Data presented are Mean ± SD
Product Healthy subjects PD patients
Hsu et al. [18] (N = 22) Study 1 (N = 27) Study 2 (N = 32) Study 3 (N = 12)
ER CD-LD 4.9 ± 2.4 4.0 ± 2.0 4.1 ± 1.5 4.1 ± 1.3
IR CD-LD 1.5 ± 0.7 1.4 ± 0.7 NA NA
CR CD-LD 2.1 ± 1.0 NA NA 3.1 ± 1.0
CD-LD-Entacapone 2.1 ± 1.0 NA 2.5 ± 1.1 NA
NA not applicable, ER extended-release, IR immediate-release, CR sustained release, LD levodopa, CD carbidopa, Cmax maximum observed
plasma concentration, SD standard deviation
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estimates of intra- and intersubject variabilities for these
parameters using pooled data from the crossover studies.
Intrasubject variability was 17.2% for log AUC? and
18.8% for log Cmax, whereas intersubject variability was
22.2% for log AUC? and 19.8% for log Cmax. These
intrasubject variabilities would be considered low accord-
ing to the commonly used regulatory definition that drugs
that exhibit intrasubject variability of[30% are considered
highly variable [26–28].
The multiple-dose pharmacokinetics of ER carbidopa-
levodopa and IR carbidopa–levodopa was compared in
patients [20]. Over the 12-h assessment period, the average
interindividual coefficient of variation for plasma concentra-
tions of levodopa after ER carbidopa–levodopa treatment was
33.2%, significantly lower than during IR carbidopa–levodopa
administered every 6 h (75.2%) or IR carbidopa–levodopa
administered every 3 h (43.0%) (p\ 0.05, Bartlett’s test).
3.8 Effect of Food on the Pharmacokinetics
of Extended-Release (ER) Carbidopa–Levodopa
Capsules
The sustained-release beads in the ER carbidopa–levodopa
capsule formulation are designed to exhibit lower drug
release below pH 7. The effect of two representative soft-
food products [Jell-O (pH 6.5) and Kozy-Shack Flan
Cre`me Caramel Pudding (pH 6.1)] with pH values above 6
was investigated to evaluate the in vitro release of levo-
dopa. Approximately 10 mL of each food was mixed with
ER component 2 beads and allowed to stand at ambient
temperature for 30 min. The beads were washed with water
until no food residue was visible and the amounts (%) of
levodopa and carbidopa remaining in the beads were
determined. Mixing ER carbidopa–levodopa with selected
soft foods with a pH of approximately 6.0 for up to 30 min
resulted in\4.5% levodopa release and did not affect the
integrity of the formulation, as demonstrated by the
insignificant amount of levodopa released upon mixing.
The effect of a high-fat meal on the pharmacokinetics of
single-dose ER carbidopa–levodopa was also investigated
in healthy volunteers [22]. In a three-period, randomized,
crossover study, subjects received two capsules of ER
carbidopa–levodopa 61.25/245 mg under fasting condi-
tions, and then, after an appropriate washout of at least
6 days, received two capsules of ER carbidopa–levodopa
61.25/245 mg after consuming a high-fat, high-calorie
breakfast as recommended by US Food and Drug Admin-
istration (FDA) and European Medicines Agency (EMA)
guidance [29, 30]. On a separate occasion, subjects
received the contents of carbidopa–levodopa capsules
sprinkled over a tablespoon of applesauce under fasting
conditions. Administration of ER carbidopa–levodopa with
a high-fat, high-calorie breakfast delayed the initial
increase in levodopa concentration by approximately 2 h,
reduced Cmax by 21%, and increased AUC? by 13%
compared with the fasted state. Sprinkling the ER car-
bidopa–levodopa capsule contents on applesauce did not
affect the pharmacokinetics [22].
4 Effect of Intrinsic Factors
on the Pharmacokinetics of ER Carbidopa–
Levodopa Capsules
The effect of various intrinsic factors, including race,
gender, age, body weight, and renal function, on the
pharmacokinetics of ER carbidopa–levodopa was evalu-
ated using dose-normalized data from studies in healthy
volunteers and patients.
4.1 Effect of Race
The vast majority (95%) of patients with PD in whom
pharmacokinetic data were available were White; there-
fore, no assessments of race on levodopa pharmacokinetics
were conducted in patients with PD. In the healthy popu-
lation, levodopa Cmax and AUC? values were 10–17%
higher in Black versus White subjects. Median time to peak
levodopa concentration and terminal half-life were com-
parable in the two groups (Table 7).
4.2 Effect of Gender
Plasma concentrations of levodopa were higher in women
compared with men, in both healthy subjects and patients
with PD. In healthy subjects, mean dose-normalized levo-
dopa Cmax values were approximately 25% greater and
AUC? values approximately 38% higher in females than
in males, while in patients with PD, mean dose-normalized
Cmax was 35% greater and AUC? was 37% higher in
females than in males. Median time to peak levodopa
concentration and terminal plasma half-life of levodopa
were comparable in men and women for both healthy
subjects and patients with PD (Table 8).
Table 6 Intersubject variability (% CV) in LD pharmacokinetics
from ER CD-LD capsules and other CD-LD products
ER CD-LD IR CD-LD CR CD-LD CD-LD-
Entacapone
Cmax 20.2 36.7 35.0 27.7
AUCt 30.9 30.0 28.8 34.9
Cmax maximum observed plasma concentration, AUCt area under the
concentration–time curve from time zero to the last measured con-
centration, ER extended-release, IR immediate-release, CR sustained
release, LD levodopa, CD carbidopa, CV coefficient of variation
A. Mittur et al.
4.3 Effect of Age
Patients with PD in whom pharmacokinetic data were
available were significantly older than healthy subjects;
93% of patients with PD were older than 50 years of age,
while 98% of healthy subjects were younger than 50 years
of age.
Dose-normalized levodopa AUC? increased with
increasing age in healthy subjects and patients with PD.
Age accounted for approximately 4% and 15% of the
variability in levodopa AUC? in healthy volunteers and
patients with PD, respectively (Online Resource Fig. 1),
and mean dose-normalized Cmax and AUC? were 27 and
52% higher, respectively, in patients with PD older than
65 years of age compared with patients younger than
50 years of age.
4.4 Effect of Body Weight
Table 9 summarizes levodopa pharmacokinetics in healthy
subjects and patients with PD, by weight. Dose-normalized
Cmax and AUC? of levodopa from ER carbidopa–levodopa
were negatively correlated with body weight in healthy
subjects and patients with PD. Body weight accounted for
approximately 18 and 31% of the observed variability in
dose-normalized Cmax and AUC? of levodopa, respec-
tively, in patients with PD (Online Resource Fig. 2). As
expected, no difference in tmax and t was observed
between the weight groups.
4.5 Effect of Renal Function
The relationship between estimated creatinine clearance, a
measure of renal function, and levodopa pharmacokinetics
was evaluated using the pooled dose-normalized pharma-
cokinetic data from studies in healthy volunteers and
patients with PD. Dose-normalized AUC? values tended to
increase with decreasing creatinine clearance in both
healthy subjects and patients with PD (Online Resource
Fig. 3). Estimated creatinine clearance explained approxi-
mately 14 and 18% of the variability in AUC? in healthy
subjects and patients with PD, respectively, and accounted
for approximately 13 and 14% of the variability in levo-
dopa Cmax in healthy subjects and patients with PD,
respectively.
Table 7 LD pharmacokinetics
for ER CD-LD capsules in
healthy subjects categorized by
race (mean ± SD)
White (N = 121) Black (N = 61) Ratio (Black/White)
Cmax (ng/mL) 793 ± 269 873 ± 224 1.10
tmax (h)
a 4.0 (0.3–7.0) 4.5 (0.5–8.0) –
t (h) 1.7 ± 0.9 1.7 ± 0.5 1.0
AUC? (ng h/mL) 3679 ± 1252 4294 ± 1284 1.17
AUC? and Cmax are dose-normalized to 245 mg
Cmax maximum observed plasma concentration, tmax time to maximum concentration, t half-life, AUC?
area under the concentration–time curve extrapolated to infinity, SD standard deviation, ER extended-
release, CD carbidopa, LD levodopa
a Median (range)
Table 8 LD pharmacokinetics
for ER CD-LD capsules in
healthy subjects and patients




b t (h) AUC? (ng h/mL)
a
Healthy subjects
Males (N = 97) 734 ± 211 4.0 (0.3–6.0) 1.7 ± 0.30 3291 ± 874
Females (N = 87) 920 ± 273 3.5 (0.3–8.0) 1.7 ± 0.78 4545 ± 1351
Subjects with PD
Males (N = 52) 1029 ± 405 1.5 (0.5–6.0) 1.9 ± 0.7c 5103 ± 2218c
Females (N = 20) 1390 ± 580 2.0 (0.5–3.0) 1.9 ± 0.9d 6975 ± 2695d
PD Parkinson’s disease, Cmax maximum observed plasma concentration, tmax time to maximum concen-
tration, t half-life, AUC? area under the concentration–time curve extrapolated to infinity, ER extended-
release, CD carbidopa, LD levodopa, SD standard deviation
a Dose normalized to 245 mg
b Median (range)
c N = 45
d N = 15
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5 Pharmacodynamics
The pharmacokinetic/pharmacodynamic relationship for
ER carbidopa–levodopa capsules has been characterized in
patients with PD using finger tapping, UPDRS Part III
score, and the incidence of dyskinesia [25]. The pharma-
codynamic models included a biophase effect site equili-
bration with a sigmoid maximum effect (Emax) transduction
for tapping and UPDRS Part III score, and an ordered
categorical model for dyskinesia. Pharmacodynamic
parameters for tapping and UPDRS Part III scores are
presented in Online Resource Table 2. The estimated half
maximal effective concentration (EC50) for tapping was
1590 ng/mL, with an equilibrium half-life of 36 min, while
the EC50 for the UPDRS Part III score was 812 ng/mL,
with an equilibrium half-life of 23 min, and the EC50 for
dyskinesia was 601 ng/mL, with an equilibrium half-life of
27 min [25].
In addition, a dose-response relationship for UPDRS
Part II plus Part III was established in levodopa-naı¨ve PD
patients using a disease progression model [31]. The model
comprised three components: a linear function describing
natural disease progression, a component describing pla-
cebo (or non-levodopa) effects, and a component describ-
ing the levodopa-specific effect. Natural disease
progression in early PD was 11.6 units/year and the half
maximal effective dose (ED50) for the total daily dose of
levodopa was 450 mg [31].
6 Discussion
Oral levodopa is rapidly absorbed across the intestinal
mucosa by amino acid transporters expressed in the prox-
imal small intestine. Therefore, oral absorption of levodopa
is largely limited to the intestinal region where these
transporters are expressed and the extent of absorption
depends on the rate at which levodopa transits through the
upper small intestine. The absolute oral bioavailability of
levodopa is dose-dependent due to capacity-limited
absorption via the active transporters. In practice, doses of
levodopa are carefully titrated in each patient to achieve
optimal efficacy. Low concentrations of levodopa in
plasma (and in the brain) can result in the reappearance of
the core symptoms of PD; however, side effects such as
motor fluctuations, occur when levels of levodopa exceed a
patient-specific threshold. Furthermore, uncontrolled and
unpredictable fluctuations in plasma and striatal concen-
trations of levodopa are thought to contribute to the
development of ‘on-off’ fluctuations, including dyskine-
sias. Therefore, the treatment of motor symptoms in PD is
most effective when plasma concentrations of levodopa are
maintained within a therapeutic range, which progressively
narrows as the disease progresses.
Although several controlled-release (CR) formulations
of levodopa (with carbidopa or benserazide) have been
developed, these formulations are associated with erratic
absorption and variable levodopa plasma concentrations
[32, 33]. In addition, the latency to onset of motor
improvement is typically 60–180 min with the CR for-
mulation due to the slower absorption. Thus, CR formu-
lations are commonly administered with IR carbidopa–
levodopa in patients, particularly for the first dose in the
morning [34, 35]. Various methods, including oral CR
formulations and duodenal infusion of levodopa, have
sought to provide continuous and sustained oral delivery of
levodopa in an effort to reduce or delay the development of
motor complications. With the exception of invasive and
often impractical continuous intraduodenal infusion of
levodopa by a pump, current regimens of oral levodopa are
beset by a limited window of effect, requiring frequent
administrations and/or unpredictable pharmacokinetics.
Table 9 Pharmacokinetics of
ER LD capsule in healthy
subjects and subjects with PD
categorized by body weight
Cmax (ng/mL)
a tmax (h)
b t (h) AUC? (ng h/mL)
a
Healthy subjects
40 to\65 kg (N = 42) 991 ± 279 4.5 (0.5–8.0) 1.7 ± 0.77 4911 ± 1504
65–91 kg (N = 119) 799 ± 224 3.5 (0.3–7.0) 1.7 ± 0.72 3744 ± 1012
C91 kg (N = 23) 631 ± 218 3.5 (0.3–6.0) 1.7 ± 0.30 2730 ± 722
Subjects with PD
40 to\65 kg (N = 8) 1509 ± 649c 1.5 (0.5–3.0)c 2.1 ± 1.1 8781 ± 2330
65–91 kg (N = 34) 1148 ± 439c 2.0 (0.5–6.0)c 1.8 ± 0.5 5457 ± 2352
C91 kg (N = 18) 917 ± 347c 2.0 (0.5–3.5)c 1.9 ± 0.8 4380 ± 1307
Cmax maximum observed plasma concentration, tmax time to maximum concentration, t half-life, AUC?
area under the concentration–time curve extrapolated to infinity, PD Parkinson’s disease, ER extended-
release, LD levodopa
a Dose normalized to 245 mg
b Median (range)
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The development of improved oral CR products of levo-
dopa has been hindered by its unfavorable properties, in-
cluding poor solubility, short plasma half-life, inconsistent
absorption due to slow or variable gastric emptying, and its
absorption being limited to the proximal small intestine.
ER carbidopa–levodopa is a new capsule formulation
that provides immediate delivery of a fraction of the
levodopa dose followed by CR from beads that provide the
remainder of the levodopa dose over an extended duration.
The pharmacokinetic profile of ER carbidopa–levodopa
capsules is characterized by an initial increase in levodopa
plasma concentrations that is comparable to IR carbidopa–
levodopa, to provide a rapid initial onset of effect. Fol-
lowing an initial plateau in levodopa concentrations at
approximately 1 h, concentrations are maintained for 4–5 h
before declining. This plasma profile provides an extended
duration of effect with a lower fluctuation in plasma
levodopa concentrations (1.5 for ER carbidopa–levodopa
capsules compared with 3.2 for IR carbidopa–levodopa).
The magnitude of rise and fall of levodopa plasma con-
centrations relative to the average concentration (i.e. the
fluctuation index) may be of particular interest for an ER
formulation. The lower the fluctuation index, the more
likely the Cmax is blunted relative to the trough, thus
improving symptom control and minimizing Cmax-related
adverse effects [21]. An ideal carbidopa–levodopa product
would have minimal fluctuation and maintain steady
levodopa concentrations over the dosing interval. Fluctu-
ations in levodopa concentrations are of particular concern
since the short duration response for levodopa is correlated
with the short peripheral pharmacokinetics. Although it
may be expected that CR formulations would have a
reduced fluctuation index, that does not always appear to
be the case for carbidopa–levodopa products. In a study
comparing multiple-dose pharmacokinetics of conventional
Sinemet tablets and Sinemet CR formulations CR3 and
CR4 in healthy volunteers, the fluctuation index was 2.45,
2.06, and 1.86, respectively [36]. The use of selective
COMT inhibitors, such as entacapone and tolcapone, is
also reported to prolong the effect of a levodopa dose.
However, this does not seem to result in an improved
fluctuation index. LeWitt and colleagues [13] compared
CR carbidopa–levodopa and combined entacapone with
carbidopa–levodopa in subjects with PD. The mean fluc-
tuation index was 2.35 for carbidopa–levodopa–entacapone
and 1.96 for CR carbidopa–levodopa. Similarly, Nyholm
et al. noted a fluctuation of 2.23 for carbidopa–levodopa–
entacapone and 1.26 for carbidopa–levodopa microtablets
in healthy subjects [37].
A detailed discussion of the potential mechanisms by
which ER carbidopa–levodopa improves the pharmacoki-
netic profile of levodopa is beyond the scope of this review;
However, some features of the formulation are worth
noting. The ER carbidopa–levodopa capsule formulation is
not designed to affect the intestinal transit characteristics of
levodopa. The formulation includes tartaric acid, an
organic acid, to modulate the drug release rate and act as an
acidifying excipient. The presence of tartaric acid in the
core of the formulation may govern the prolonged and slow
release of levodopa by interfering with the dissolution of
the enteric coat. In intestinal epithelial cell lines (Caco-2,
IEC-6), an acidic medium has been shown to stimulate the
transport of levodopa [2]. Tartaric acid inhibits P-glyco-
protein (P-gp) and the efflux of P-gp substrates from the
serosal to mucosal side in epithelial cells. Furthermore, it
may be noted that levodopa is a substrate for P-gp. Sali-
cylic acid has been shown to facilitate the absorption of
levodopa after rectal administration in rats by a mechanism
that requires its presence in the rectal membrane [38].
Studies have shown that exogenous administration of
ascorbic acid improves levodopa absorption (Cmax and
AUC) in PD patients with poor levodopa bioavailability
[39, 40]. Therefore, one may speculate that tartaric acid
cumulatively extends the window of levodopa absorption
in the gastrointestinal tract by promoting an acidic milieu
in regions of the intestine where levodopa is a substrate for
pH-sensitive amino acid transporters or exchangers, by
inhibiting P-gp-mediated efflux from the more distal
regions of the intestine or by enhancing its mucosal per-
meation via paracellular pathways. Although previous
studies have looked into the role an acid may play in
levodopa formulations, there is uncertainty whether the
addition of an acid aids in extending the absorption of oral
levodopa, and the exact mechanism of action of tartaric
acid in the ER carbidopa–levodopa formulation has not
been completely elucidated.
On a dose-normalized basis, levodopa Cmax values for
ER carbidopa–levodopa capsules are approximately 30%
and AUC values are approximately 70% compared with IR
carbidopa–levodopa. Following oral administration of ER
carbidopa–levodopa capsules, levodopa concentrations are
maintained above 50% Cmax for a longer duration than with
other carbidopa–levodopa formulations. ER carbidopa–
levodopa also exhibits low (approximately 20%) intrasub-
ject variability in levodopa Cmax and AUC?, and the
intersubject variability is lower or comparable with other
carbidopa–levodopa products. These pharmacokinetic
characteristics mean that when patients are converted to ER
carbidopa–levodopa from their current levodopa regimen,
the total daily dose of levodopa from ER carbidopa–levo-
dopa will be approximately twofold higher compared with
the current levodopa dose. The total daily dose of ER
carbidopa–levodopa capsules is administered using a
combination of the available dose strengths as three to five
divided doses based on patient characteristics (e.g. disease
stage, total dose, and patient propensity to experience
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dyskinesia). In spite of the higher total levodopa dose with
ER carbidopa–levodopa capsules, peak levodopa concen-
trations are not expected to be higher than following the
patient’s typical IR carbidopa–levodopa dose.
The effect of food on the pharmacokinetics of single-
dose ER carbidopa–levodopa capsules was investigated in
healthy subjects [22]. In the phase III clinical trials,
patients with PD were advised to take their ER carbidopa–
levodopa capsules in the same way as they would take their
usual levodopa medication with respect to food intake.
Administration of the ER carbidopa–levodopa capsules
with a high-fat breakfast in healthy subjects did not result
in dose dumping and there was no effect on the overall
extent of absorption of levodopa (AUC). A high-fat
breakfast delayed the absorption of levodopa: tmax was
1–2 h later and levodopa Cmax decreased by approximately
21% [22]. Although there was a slower rate of absorption
with a high-fat meal, the overall duration of time that
levodopa concentrations were maintained above 50% Cmax
was longer (7.0 h) compared with the fasting state (4.4 h).
Administration of the ER carbidopa–levodopa capsule
contents sprinkled onto a small quantity of applesauce did
not compromise the rate or extent of absorption of levo-
dopa versus ER carbidopa–levodopa capsules swallowed
whole in a fasted state [22]. In addition, in vitro assess-
ments with representative foods at a pH value of approxi-
mately 6 indicated that the capsule formulation is robust
and does not result in dose dumping. Swallowing diffi-
culties are not uncommon in subjects with PD [41, 42] and,
in these patients, the ability to sprinkle the contents of ER
carbidopa–levodopa capsules onto a small quantity of soft
food, such as applesauce or pudding, to facilitate dosing
may be advantageous.
Results of the effect of food on levodopa pharmacoki-
netics from standard and CR formulations have been
mixed. Baruzzi and colleagues examined the effect of
standardized meals on the pharmacokinetic of levodopa
(50/200 mg) in PD patients taking Sinemet (car-
bidopa:levodopa 1:10) [43]. When levodopa was adminis-
tered after meals, levodopa tmax increased threefold (from
45 to 134 min) compared with that in the fasted state. The
extent of levodopa absorption (AUC6) and Cmax in the fed
state were lower by an average of 15% and 30%, respec-
tively [43]. In mild to moderately severe PD patients,
levodopa Cmax and AUC4 after administration of a single
carbidopa–levodopa CR (50/200 mg carbidopa–levodopa)
tablet in the fasted state were, on average, 16–17% higher
relative to that following a protein-rich meal [44]. Contin
et al. reported that the intake of a single dose of Sinemet
CR (50/200 mg carbidopa–levodopa) by patients with mild
to moderately severe PD after a standard low-protein meal
reduced levodopa AUC6 by 24%, Cmax was unchanged, and
tmax was delayed [45]. These confounding effects of food
on the levodopa pharmacokinetics of IR and CR car-
bidopa–levodopa may be attributed to various factors,
including differences in formulations, different ratios of
carbidopa:levodopa, study designs, and specific composi-
tions of food in each study.
High-protein meals have been reported to impair the
absorption and clinical response to levodopa, while low-
protein diets have been associated with enhanced clinical
response [46]. Because there is no impact on the pharma-
cokinetics of levodopa when it is administered with a high-
or low-protein meal compared with the fasted state [47],
the mechanism of the interaction is believed to be via
competition through an amino acid transport system at the
BBB rather than at the gastrointestinal tract. This obser-
vation is supported by a positron emission tomography
(PET) study conducted with [18F]fluorodopa which showed
that elevating large neutral amino acids in plasma two- to
threefold reduced the entry of [18F]fluorodopa into the
brain [48]. Since this interaction between levodopa and
amino acids occurs at the BBB, a similar interaction would
be expected with ER carbidopa–levodopa capsules. In
summary, a high-fat, high-calorie meal may delay levo-
dopa absorption and decrease levodopa Cmax. Sprinkling
the ER carbidopa–levodopa capsule contents on applesauce
did not affect levodopa pharmacokinetics compared with
the intact capsule. Similar to other carbidopa–levodopa
products, patients should be cautioned that taking ER
carbidopa–levodopa with foods rich in proteins or amino
acids may interfere with the clinical effects of levodopa.
Based on a pooled analysis of pharmacokinetic data in
healthy volunteers and patients with PD, levodopa expo-
sure after administration of ER carbidopa–levodopa cap-
sules was higher in PD patients compared with healthy
subjects (37% for Cmax and 44% for AUC), likely because
the PD patients were older (mean 62.8 years) compared
with the healthy cohort (mean 30.9 years). Rainero and
colleagues studied the pharmacokinetics of standard car-
bidopa–levodopa in 11 healthy volunteers (mean
58.3 years) and 16 patients with PD (mean 63.1 years)
[49], and noted that the AUC? was 3.38 lg h/mL in PD
patients and 3.06 lg h/mL in healthy subjects, while Cmax
values were 1.35 lg/mL in PD patients and 1.07 lg/mL in
healthy subjects. These findings are similar to those noted
in the current analysis with ER carbidopa–levodopa
capsules.
Dose-normalized levodopa Cmax and AUC? following
administration of ER carbidopa–levodopa capsules were
higher in females (25–35% for Cmax, 37–38% for AUC?)
than in males in healthy subjects and patients with PD.
These results are consistent with other carbidopa–levodopa
formulations [50–53]. Published studies demonstrate a
significant effect of gender on levodopa exposure (higher
concentrations in females), even after correction for body
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weight. Kompoliti and colleagues examined the effects of
gender on the pharmacokinetics of levodopa following a
single dose of carbidopa–levodopa (25/100 mg) in fasted
PD subjects [53]. The mean age in their study was
69.3 years for women and 68.9 years for men, and all
weighed within ±15% of the predicted ideal weight. The
results of this study showed that women had significantly
higher mean body-weight-normalized levodopa AUC6
(82%) and higher mean Cmax (58%), but comparable
median tmax, compared with men. In fed PD subjects
administered an oral dose of levodopa 100 or 250 mg with
an AADC inhibitor, body-weight-normalized levodopa
AUC, but not Cmax, was significantly (p\ 0.003) greater in
women than in men [52, 54], while in fasted PD subjects
administered oral carbidopa–levodopa 25/250 mg, levo-
dopa AUC and Cmax were significantly higher in females
(31% and 28%, respectively) than in males [52]. The
authors noted that women were significantly lighter and
more dyskinetic than men. By comparison, a population
analysis of fasted subjects with mild to severe PD (age
34–78 years, disease duration of 0.8–24 years) adminis-
tered a single oral dose of benserazide-levodopa (25/
100 mg) reported that the pharmacokinetics of levodopa
(apparent volume of distribution [V/F], absorption rate
constant [ka], and elimination rate constant [kel]) were
independent of patient characteristics, including gender
[55]. The pharmacokinetic data with ER carbidopa–levo-
dopa capsules indicate that women exhibit an approxi-
mately 33% higher levodopa Cmax and AUC? compared
with men, similar to several other reports in the literature.
Since dosing for PD patients is accomplished by careful
individual titration, these differences are likely of minor
relevance in treating PD patients.
Consistent with our observations with ER carbidopa–
levodopa capsules, the AUC of levodopa was negatively
correlated with body weight in male and female subjects
with PD following a single oral dose of carbidopa–levo-
dopa 25/250 mg [52]. Other studies have arrived at similar
conclusions regarding the negative correlation of levodopa
AUC and body weight, with increased prevalence of
dyskinesias in subjects of lower body weight
[50, 52, 56, 57].
Levodopa AUC and age were positively correlated in
both healthy subjects and patients with PD (Online
Resource Fig. 4). These results are consistent with reports
in the literature with other formulations of levodopa and a
decarboxylase inhibitor. Contin and colleagues [58] noted
that following administration of levodopa 100 mg with
benserazide 25 mg, levodopa AUC was significantly
greater in PD patients older than 65 years of age than those
under 65 years of age (547 vs. 428 lmol/l). Similarly,
Robertson et al. compared the pharmacokinetics of oral
levodopa (125 mg) with carbidopa in elderly (69–76 years
of age) and young (21–22 years of age) healthy volunteers
[59], and noted a higher AUC for levodopa in elderly
versus young subjects (4530 vs. 2926 ng h/mL; p\ 0.01).
The Cmax values were comparable in the two groups
(1922 ng/mL in the elderly subjects compared with
1712 ng/mL in the young subjects). These differences,
while statistically significant, were considered modest and
not likely to impact dosing.
In the presence of AADC inhibitors, the majority of a
levodopa dose is cleared by non-renal elimination mecha-
nisms, and renal excretion of intact levodopa accounts for
only approximately 10% of clearance [19]. Renal impair-
ment is considered unlikely to have a clinically significant
effect on levodopa pharmacokinetics following the
administration of ER carbidopa–levodopa since renal
excretion of levodopa accounts for \10% of the overall
clearance of levodopa. Thus, while impaired renal function
may contribute to some increased exposure of levodopa,
the contribution is likely to be minor and not considered
clinically significant. carbidopa–levodopa has been used in
the treatment of secondary restless legs syndrome in sub-
jects receiving hemodialysis and this has not highlighted
any significant safety concerns [60–62]. In clinical prac-
tice, the dose of levodopa generally does not have to be
adjusted in patients with renal failure [63]. Given the minor
contribution of estimated creatinine clearance to the vari-
ability in levodopa exposures, renal impairment is unlikely
to have a clinically significant effect on ER carbidopa–
levodopa pharmacokinetics.
The pharmacodynamics of ER carbidopa–levodopa was
characterized in patients with PD who were naı¨ve to
levodopa [31] and patients with advanced PD [20, 25]. A
disease progression pharmacodynamic model was devel-
oped using UPDRS Part II plus III in patients with early PD
who were naı¨ve to levodopa [31]. The pharmacodynamic
model indicated that the linear progression disease rate was
11.6 UPDRS units/year. The maximum reduction in the
UPDRS Part II plus III score of IPX066 at steady state was
76.7% of baseline values, and the estimated ED50 for
levodopa from IPX066 was 450 mg/day. Pharmacody-
namic parameters estimated for ER carbidopa–levodopa
capsules were consistent with published reports [64, 65]. In
patients with advanced PD, the motor effects (finger tap-
ping, UPDRS Part III, and investigator-rated assessment of
motor state) following single and multiple dosing of ER
carbidopa–levodopa capsules was described using an effect
compartment with a sigmoid Emax pharmacodynamic
model [25]. The estimated pharmacodynamic parameters
(Online Resource Table 2) for UPDRS Part III (Emax 63%
of baseline; EC50 812 ng/mL; ke0 1.80 h
-1; c 2.5) are
comparable with those reported by Troco´niz et al. [66]
(Emax 49% of baseline; EC50 951 ng/mL; ke0 2.01 h
-1; c
6.2). Similarly, the pharmacodynamic parameters
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estimated for the tapping rate are comparable with pub-
lished reports [55, 67].
The new ER carbidopa–levodopa capsule product is
approved in the USA and the EU for the treatment of PD
based on studies demonstrating the safety and efficacy in
both early and advanced stages of the disease. Data from a
9-month safety and efficacy study in early and advanced
PD patients indicates a favorable tolerability and efficacy
profile for ER carbidopa–levodopa capsules [68].
7 Conclusions
In summary, the pharmacokinetic and pharmacodynamic
studies discussed in this review support the use of ER
carbidopa–levodopa capsules as an efficacious and well-
tolerated treatment for patients with PD, with possible
benefits over other levodopa formulations.
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